

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	April 30, 2021

**ARIKAYCE<sup>®</sup> (amikacin liposome inhalation suspension)**

**LENGTH OF AUTHORIZATION:** Up to one year

**REVIEW CRITERIA:**

- Patient must be ≥ 18 years of age.
- Patient has confirmed diagnosis of refractory Mycobacterium avium complex (MAC) lung disease.
- Prescriber is a pulmonologist or infectious disease specialist.
- Patient has failed to achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug treatment regimen (laboratory documentation required).
- Arikayce will be part of a combination antibacterial drug regimen.

**DOSING AND ADMINISTRATION:**

- Administer once daily by oral inhalation the contents of one 590 mg/8.4 mL vial via nebulizer.